The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Barc is a very unloved product at the moment.....but that won't last forever......I think the sum of the parts ( NAV) is quite significantly higher than what the market currently value the sp at.... Why has the initial euphoria of a well known activist inventor who has accumulated 5% Benn lost so quickly? Well on the macro level the USA declaring a trade war on China is alive and well and caused the 5 th biggest drop in history.....every share has been hit nearly....and it ain't finished yet On the company level, the new activist investor should have refrained from saying in their first interview that they could double the current share price....market clearly not impressed or convinced....I don't blame them. You say you will go back to property...not without risk but still a good investment.......the main difference is that you don't check the value of your house everyday.....but you will your shares... It just requires a different mindset in my opinion.......but hell I am no expert.. Good luck whatever u decide....but I think this is a solid company with a poor record but with a good chance of a RE- rate at some point in the future.
Dow tanking on trade war fears.... As I said the other day to one of the posters...if they opened a short here on macro market jitters....well done.... I'm still for the long term here........most things drop in a market tempest...
That size of purchase will take some digesting.....a bit like eating an elephant for dinner!! I fear we will pay top dollar at 20 billion Long term could be good....short term to medium term leaves us without a pot financially
Edward Bramson’s activist investment fund has taken a stake of just over 5 per cent in Barclays, becoming a top five shareholder in the British bank and increasing pressure for it to turn round its faltering performance. Barclays said in a statement on Monday that entities controlled by Sherborne, Mr Bramson’s investment vehicle, had acquired voting rights over 5.16 per cent its issued share capital. The bank said that made the activist investor its fourth largest shareholder behind Capital Group, the Qatar Investment Authority and BlackRock. Mr Bramson, who was born in London but moved to New York more than 30 years ago, is understood to have met with members of the Barclays board to discuss the bank’s annual results and to hear its outlook for the coming year. Barclays said he had not made any specific demands, such as to gain a seat on the bank’s board or to change its strategy. Mr Bramson stands among the top UK investment institutions after successful investments in several companies. The activist investor has led several high profile corporate turnrounds in the last few years, including F&C Asset Management, the fund manager, and Electra, the private equity group. Sherborne’s investment in Barclays is the second time in a few months that a hedge fund has made a large bet on the bank’s shares after Tiger Global in the US invested about $1bn in its shares last year. Barclays, which reported a full-year loss of £1.9bn last month, was one of the worst performing shares in its sector in 2017, falling more than 12 per cent while the Stoxx Europe 600 Banks index rose 7.5 per cent. But its shares have rallied recently, after the bank announced plans to restore its dividend back to where it was before being cut two years ago and said it would benefit from US tax cuts and a revival of volatility in financial markets since the start of this year. Jes Staley, chief executive, has made a big bet that he can turn round the performance of Barclays’ investment bank, which has been hit by a long period of low volatility in financial markets and changes to regulation on bank capital requirements.
Shorting...really? 80 p under NAV , activist shareholder now accumulating, restructuring announced as complete with growing dividend projection in last update... What price to you see it collapsing to?? Genuinely interested...if your planning a macro pullback of the markets...I can see your point....but would pick much higher ( unjustified) priced shares that would have further to drop. I'm now above b/e...sitting on the side biding my time...but definitely in the long camp
The Telegraph: Short-sellers accelerate bets against troubled AA. http://google.com/newsstand/s/CBIw-f6X8jc
Good luck. I am sitting on the sides at the moment..and will probably buy...but not yet and not as many. The Waitress and John Lewis slump in profits (-77%) is a good indication of how retail is changing away from town centres to large superstores ( Cheshire Oaks as an example) and of course internet. They are also good comparison company's to MKS. I think MKS has some further cost cutting and streamlining personally. I agree longer term they will prevail...but feel they have to face some further lows. In 3 yrs your entry point will look good. I
If anyone can pull off a decent bid for our potential new health care wing it is S.D. Below from 2010 when he left GS for GSK https://www.telegraph.co.uk/finance/newsbysector/epic/gsk/7990480/Goldman-Sachs-rainmaker-Simon-Dingemans-to-join-GlaxoSmithKline.html
didn't realise sorry..actual Article GlaxoSmithKline plc 47.5% Potential Upside Indicated by HSBC Posted by: Amilia Stone 27th February 2018 GlaxoSmithKline plc with EPIC/TICKER (LON:GSK) had its stock rating noted as �Reiterates� with the recommendation being set at �BUY� today by analysts at HSBC. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. HSBC have set their target price at 1925 GBX on its stock. This is indicating the analyst believes there is a potential upside of 47.5% from the opening price of 1305 GBX. Over the last 30 and 90 trading days the company share price has decreased 44 points and decreased 22.5 points respectively. The 52 week high share price is 1724.5 GBX while the 52 week low for the share price is 1235.2 GBX. GlaxoSmithKline plc has a 50 day moving average of 1,314.69 GBX and a 200 day moving average of 1,315.22. There are currently 500,000,000 shares in issue with the average daily volume traded being 8,890,364. Market capitalisation for LON:GSK is �64,541,817,547 GBP.
https://www.***************************/glaxosmithkline-plc-47-5-potential-upside-indicated-by-hsbc/412746345
So nearly bought in last week......but didn't!!!! Well done and good luck....good day
The Independent: Energy price cap: Government to introduce legislation to limit how much power firms can charge. http://google.com/newsstand/s/CBIwjdr55Tc
https://www.fiercepharma.com/vaccines/glaxosmithkline-tops-its-peers-7-16b-2017-vaccine-sales
Whilst I thought the RNS was a grovelling apology for pretty poor performance and the fact that the company are bleeding customers, EPS down, adjusted earnings down etc....I have just perplexed myself by making an opening purchase at 1.43..... Why?????The company does not rely on high risk R&D, the products are cash generative and customers will come back from the cheaper " internet only customer service" deals they are on when they can't resolve their issues on the phone. But the main reason I've bought in (3-5 yr window) is that disclosed short interest in the company is a v meagre 0 .6%............just compare this to AA or provident etc......the big boys and hedge funds see no profit in shorting this indicating the bottom was in the 120's. Do I think this is a well managed stellar company???? God no. Do I think there is value here up to @2.20...oh yes